UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 26

Sortiert nach

Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer

Molecular cancer therapeutics, 2014-04, Vol.13 (4), p.890-901

2014

Volltextzugriff (PDF)

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis

Nature medicine, 2009-07, Vol.15 (7), p.781-787

2009

Volltextzugriff (PDF)

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

Blood, 2007-11, Vol.110 (9), p.3281-3290

2007

Volltextzugriff (PDF)

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

Cancer research (Chicago, Ill.), 2007-07, Vol.67 (13), p.6383-6391

2007

Volltextzugriff (PDF)

Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)

Journal of medicinal chemistry, 2009-05, Vol.52 (9), p.3028-3038

2009

Volltextzugriff (PDF)

Validation of the Proteasome as a Therapeutic Target in Plasmodium Using an Epoxyketone Inhibitor with Parasite-Specific Toxicity

Chemistry & biology, 2012-12, Vol.19 (12), p.1535-1545

2012

Volltextzugriff (PDF)

The inactivation gate of the Shaker K+ channel behaves like an open-channel blocker

Neuron (Cambridge, Mass.), 1991-11, Vol.7 (5), p.743-753

1991

Volltextzugriff (PDF)

Cell cycle regulatory E3 ubiquitin ligases as anticancer targets

Drug resistance updates, 2002-12, Vol.5 (6), p.249-258

2002

Volltextzugriff (PDF)

A Novel Splice Variant of the Cell Death-promoting Protein BAX

The Journal of biological chemistry, 1998-05, Vol.273 (19), p.11930-11936

1998

Volltextzugriff (PDF)

Abstract 1416: CB-839, a novel potent and selective glutaminase inhibitor, has broad antiproliferative activity in cell lines derived from both solid tumors and hematological malignancies

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.1416-1416

2014

Volltextzugriff (PDF)

ralGDS family members interact with the effector loop of ras p21

Molecular and Cellular Biology, 1994-11, Vol.14 (11), p.7483-7491

1994

Volltextzugriff (PDF)

Erratum: A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis

Nature medicine, 2009-11, Vol.15 (11), p.1333-1333

2009

Volltextzugriff (PDF)

The Proteasome Inhibitor PR-171 Inhibits Cell Growth, Induces Apoptosis, and Overcomes De Novo and Acquired Drug Resistance in Human Multiple Myeloma Cells

Blood, 2005-11, Vol.106 (11), p.1575-1575

2005

Volltextzugriff (PDF)

Immunoproteasome-Selective Keto-Epoxide Inhibitors: Potential Therapeutic Agents for the Treatment of Hematological Disorders

Blood, 2006-11, Vol.108 (11), p.4392-4392

2006

Volltextzugriff (PDF)

The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance

Blood, 2006-11, Vol.108 (11), p.3461-3461

2006

Volltextzugriff (PDF)

Identification of Peptide Epoxy-Ketone Proteasome Inhibitors with Differential Active Site Selectivity

Blood, 2006-11, Vol.108 (11), p.4398-4398

2006

Volltextzugriff (PDF)

Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma

Blood, 2005-11, Vol.106 (11), p.1576-1576

2005

Volltextzugriff (PDF)

A Proteasome Specific Binding Assay for Quantitation of Constitutive and Immunoproteasome Active Sites

Blood, 2005-11, Vol.106 (11), p.2472-2472

2005

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics and Anti-Tumor Efficacy of PR-171, a Novel Inhibitor of the 20S Proteasome

Blood, 2005-11, Vol.106 (11), p.609-609

2005

Volltextzugriff (PDF)

Biochemical and Cellular Characterization of the Novel Proteasome Inhibitor PR-171

Blood, 2005-11, Vol.106 (11), p.1588-1588

2005

Volltextzugriff (PDF)

Nigrostriatal lesion alters neurophysiological responses to selective and nonselective D-1 and D-2 dopamine agonists in rat globus pallidus

Synapse (New York, N.Y.), 1990, Vol.5 (2), p.83-93

1990

Volltextzugriff (PDF)

Acute reduction of dopamine levels alters responses of basal ganglia neurons to selective D-1 and D-2 dopamine receptor stimulation

European journal of pharmacology, 1988-08, Vol.152 (3), p.289-300

1988

Volltextzugriff (PDF)

ralGDS Family Members Interact with the Effector Loop of ras p21

Molecular and cellular biology, 1994-11, Vol.14 (11), p.7483-7491

1994

Volltextzugriff (PDF)

POLR1A variants underlie phenotypic heterogeneity in craniofacial, neural, and cardiac anomalies

American journal of human genetics, 2023-05, Vol.110 (5), p.809-825

2023

Volltextzugriff (PDF)

Weight Change During the Postintervention Follow-up of Look AHEAD

Diabetes care, 2022-06, Vol.45 (6), p.1306-1314

2022

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(26)

Sprache

Englisch
(26)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(13)
Science & Technology
(13)
Animals
(12)
Humans
(10)
Mice
(7)
Biological And Medical Sciences
(6)
Medical Sciences
(5)
Oligopeptides - Pharmacology
(5)
Pharmacology. Drug Treatments
(5)
Rats
(5)
Antineoplastic Agents - Pharmacology
(4)
Biochemistry & Molecular Biology
(4)
Male
(4)
Pharmacology & Pharmacy
(4)
Antineoplastic Agents
(3)
Apoptosis
(3)
Oligopeptides - Therapeutic Use
(3)
Oncology
(3)
Proteasome Inhibitors
(3)
Administration, Oral
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)

Validation of the Proteasome as a Therapeutic Target in Plasmodium Using an Epoxyketone Inhibitor with Parasite-Specific Toxicity

The inactivation gate of the Shaker K+ channel behaves like an open-channel blocker

Cell cycle regulatory E3 ubiquitin ligases as anticancer targets

A Novel Splice Variant of the Cell Death-promoting Protein BAX

Abstract 1416: CB-839, a novel potent and selective glutaminase inhibitor, has broad antiproliferative activity in cell lines derived from both solid tumors and hematological malignancies

ralGDS family members interact with the effector loop of ras p21

Erratum: A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis

The Proteasome Inhibitor PR-171 Inhibits Cell Growth, Induces Apoptosis, and Overcomes De Novo and Acquired Drug Resistance in Human Multiple Myeloma Cells

Immunoproteasome-Selective Keto-Epoxide Inhibitors: Potential Therapeutic Agents for the Treatment of Hematological Disorders

The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance

Identification of Peptide Epoxy-Ketone Proteasome Inhibitors with Differential Active Site Selectivity

Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma

A Proteasome Specific Binding Assay for Quantitation of Constitutive and Immunoproteasome Active Sites

Pharmacokinetics, Pharmacodynamics and Anti-Tumor Efficacy of PR-171, a Novel Inhibitor of the 20S Proteasome

Biochemical and Cellular Characterization of the Novel Proteasome Inhibitor PR-171

Nigrostriatal lesion alters neurophysiological responses to selective and nonselective D-1 and D-2 dopamine agonists in rat globus pallidus

Acute reduction of dopamine levels alters responses of basal ganglia neurons to selective D-1 and D-2 dopamine receptor stimulation

ralGDS Family Members Interact with the Effector Loop of ras p21

POLR1A variants underlie phenotypic heterogeneity in craniofacial, neural, and cardiac anomalies

Weight Change During the Postintervention Follow-up of Look AHEAD

Suchergebnisse filtern